Moderate

Immune thrombocytopenia (ITP) - management

ITP mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Immune-mediated platelet destruction and impaired production, a diagnosis of exclusion. Treatment is guided by bleeding and platelet count rather than number alone, with corticosteroids first line and thrombopoietin receptor agonists prominent in second line.

Red flags

  • Intracranial or major GI bleeding
  • Platelets <10-20 x10^9/L with wet purpura/mucosal bleeding
  • New neurological symptoms
  • Coexisting anaemia from blood loss or haemolysis
  • Pregnancy with severe thrombocytopenia

Assessment

Differential diagnosis

  • Drug-induced thrombocytopenia
  • Thrombotic microangiopathy (TTP/HUS)
  • Marrow infiltration/failure
  • Hypersplenism
  • Pseudothrombocytopenia (EDTA)
  • Secondary ITP (SLE, HIV, HCV, CLL, H. pylori)

Investigations

  • FBC and blood film (isolated thrombocytopenia, exclude clumping/schistocytes)
  • Review medications and recent infection
  • HIV, hepatitis C, H. pylori testing
  • Immunoglobulins and autoimmune screen where indicated
  • Direct antiglobulin test if anaemia (Evans)
  • Bone marrow only if atypical features or age/treatment-refractory

Management

  • Confirm isolated thrombocytopenia and exclude secondary causes and pseudothrombocytopenia
  • Base treatment decisions on bleeding and risk, not the platelet number alone
  • Observe without treatment if platelets are adequate (often >30 x10^9/L) and no bleeding
  • Start corticosteroids first line - prednisolone taper or short high-dose dexamethasone pulses
  • Add IV immunoglobulin for severe bleeding or when a rapid rise is needed (e.g. before surgery)
  • Give platelet transfusion only for life-threatening bleeding, alongside IVIg/steroids
  • For steroid-dependent or relapsing disease move to second line: thrombopoietin receptor agonists or rituximab
  • Consider fostamatinib or splenectomy in refractory cases
  • Treat secondary causes (eradicate H. pylori, treat HIV/HCV)
  • Provide thrombosis awareness (TPO-RAs and recovery raise VTE risk) and monitor counts

Drugs & doses

Prednisolone 1 mg/kg PO daily (max 80 mg) then taper
Dexamethasone 40 mg PO once daily for 4 days (pulsed, repeatable)
IV immunoglobulin 1 g/kg IV, repeat at 48 h if needed
Eltrombopag 50 mg PO once daily (25 mg in East Asian patients), titrate to response
Romiplostim 1 mcg/kg SC weekly, titrate to max 10 mcg/kg; rituximab 375 mg/m2 IV weekly x4

Disposition

Outpatient haematology for stable disease; admit for bleeding or very low counts; emergency management for intracranial haemorrhage.

Complications & pitfalls

  • Life-threatening haemorrhage (uncommon, mainly very low counts)
  • Steroid toxicity and dependence
  • Thrombosis with TPO-RAs and on recovery
  • Chronic relapsing disease
  • Post-splenectomy infection risk

Exam pearls

  • Treat the patient's bleeding, not the platelet count
  • Platelet transfusions are reserved for life-threatening bleeding (rapidly consumed otherwise)
  • Pulsed dexamethasone gives durable responses with fewer cumulative steroid effects
  • TPO-RAs and clinical recovery both increase thrombotic risk
  • Always screen for HIV, HCV and H. pylori

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.